Journal of Neuroinflammation · 2022 · 25 citations · 40 references
Life SciencesNeurosciencePharmacologyInflammationMolecular NeuroscienceNeurodegenerationBlood-brain Barrier BiologyBlood-brain Barrier DysfunctionBlood-brain Barrier PharmacologyNeuroinflammationNeuroprotectionTraumatic Brain InjuryBlood-brain Barrier PermeabilityHypoxia-inducible Factor ActivationHypoxia-inducible Factor SignalingMultiple Sclerosis NeuroprotectionNeuroprotective AgentsNeuroprotective MechanismsRodent Brain InjuryTraumatic Brain Injury Neuroprotection
BACKGROUND: agonist that also activates the hypoxia inducible factor (HIF) pathway. VCE-004.8 shows potent antifibrotic, anti-inflammatory and neuroprotective activities and it is now in Phase II clinical trials for systemic sclerosis and multiple sclerosis. Herein, we investigated the mechanism of action of VCE-004.8 in the HIF pathway and explored its efficacy in a preclinical model of TBI. METHODS: Using a phosphoproteomic approach, we investigated the effects of VCE-004.8 on prolyl hydroxylase domain-containing protein 2 (PHD2) posttranslational modifications. The potential role of PP2A/B55α in HIF activation was analyzed using siRNA for B55α. To evaluate the angiogenic response to the treatment with VCE-004.8 we performed a Matrigel plug in vivo assay. Transendothelial electrical resistance (TEER) as well as vascular cell adhesion molecule 1 (VCAM), and zonula occludens 1 (ZO-1) tight junction protein expression were studied in brain microvascular endothelial cells. The efficacy of VCE-004.8 in vivo was evaluated in a controlled cortical impact (CCI) murine model of TBI. RESULTS: Herein we provide evidence that VCE-004.8 inhibits PHD2 Ser125 phosphorylation and activates HIF through a PP2A/B55α pathway. VCE-004.8 induces angiogenesis in vivo increasing the formation of functional vessel (CD31/α-SMA) and prevents in vitro blood-brain barrier (BBB) disruption ameliorating the loss of ZO-1 expression under proinflammatory conditions. In CCI model VCE-004.8 treatment ameliorates early motor deficits after TBI and attenuates cerebral edema preserving BBB integrity. Histopathological analysis revealed that VCE-004.8 treatment induces neovascularization in pericontusional area and prevented immune cell infiltration to the brain parenchyma. In addition, VCE-004.8 attenuates neuroinflammation and reduces neuronal death and apoptosis in the damaged area. CONCLUSIONS: This study provides new insight about the mechanism of action of VCE-004.8 regulating the PP2A/B55α/PHD2/HIF pathway. Furthermore, we show the potential efficacy for TBI treatment by preventing BBB disruption, enhancing angiogenesis, and ameliorating neuroinflammation and neurodegeneration after brain injury.
40
3D Slicer as an image computing platform for the Quantitative Imaging Network
Andriy Fedorov, Reinhard Beichel, Jayashree Kalpathy–Cramer et al. · Magnetic Resonance Imaging · 2012 · 8.9K citations · Full text
Arts, Computer Science, Radiology +12
Estimating the global incidence of traumatic brain injury
Michael C. Dewan, Abbas Rattani, Saksham Gupta et al. · Journal of neurosurgery · 2018 · 3.2K citations
Spencer L James, Alice Theadom, Richard G. Ellenbogen et al. · The Lancet Neurology · 2018 · 2K citations · Full text